Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
90 hedge funds and large institutions have $103M invested in Cascadian Therapeutics, Inc. in 2015 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 16 reducing their positions, and 12 closing their positions.
131% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 16
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
5% more funds holding
Funds holding: 86 → 90 (+4)
4% more capital invested
Capital invested by funds: $99.9M → $103M (+$3.5M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more call options, than puts
Call options by funds: $91K | Put options by funds: $91K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$5.77M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$2.45M |
| 3 |
BC
Broadfin Capital
New York
|
+$2.45M |
| 4 |
First Eagle Investment Management
New York
|
+$2.12M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.17M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.85M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.8M |
| 4 |
QF
QVT Financial
New York
|
-$1.18M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$813K |
CASC Hedge Fund Activity: Q1 2015 in Review
90 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q1 2015, worth a combined $103M — up 3.5% from $99.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CASC positions and 12 closed out — a net gain of 4 holders — while 37 added to existing stakes and 16 trimmed.
The largest buyer was Franklin Resources, adding an estimated $5.77M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $2.17M sold.
- 90 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q1 2015, up from 86 in Q4 2014.
- Funds reported $103M of Cascadian Therapeutics, Inc. stock for Q1 2015, up 3.5% quarter-over-quarter.
- 16 funds opened new Cascadian Therapeutics, Inc. positions in Q1 2015 and 12 closed out, a net change of +4 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q1 2015 was Franklin Resources, an estimated $5.77M added.
- The largest Cascadian Therapeutics, Inc. seller in Q1 2015 was Driehaus Capital Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q1 2015.